Skip to main content

Harbour Bio to Start China Trials of CLTA-4/PD-1 Combo in Two Additional Cancers

Harbour BioMed was approved to start China trials of its next-gen CLTA-4 candidate in combination with its PD-1 for two new indications: hepatocellular carcinoma and neuroendocrine tumor/neuroendocrine carcinoma. HBM believes HBM4003, a fully human anti-CTLA-4 mAb, has the potential to improve efficacy while reducing toxicity as a monotherapy and combo-therapy. Earlier this year, the CLTA-4/PD-1 combination started China trials for NSCLC. Harbour is headquartered in Cambridge , MA , with discovery operations in Rotterdam and development labs in Suzhou . More details.... Stock Symbol: (HK: 02142) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.